Literature DB >> 15713554

Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.

Gennady Rezapkin1, Javier Martin, Konstantin Chumakov.   

Abstract

A new block-ELISA test for quantitative evaluation of relative reactivity of antigenic sites was developed and used to reveal the detailed epitope structure of inactivated poliovirus vaccines (IPV) and live poliovirus strains. Poliovirus was captured on ELISA plates coated with rabbit anti-poliovirus IgG and blocked by monoclonal antibodies (Mabs) specific to individual epitopes before the remaining reactive antigenic sites were quantified by polyclonal anti-poliovirus IgG conjugate. The decrease of conjugate binding by the pre-treatment with a Mab reflects its contribution to the overall reactivity of poliovirus antigen. The level of block activity of Mabs for a given antigen can be expressed as a percent of reduction of antigenic reactivity as determined by ELISA test. It can be normalized by expressing this value as a ratio to the block activity of a reference sample. The data on the blocking-activity of a panel of monoclonal antibodies specific to different antigenic sites represents the epitope composition (antigenic profile) of a sample. Quantitative differences in epitope composition were determined for nine samples of inactivated poliovirus vaccine (IPV) and compared with the International Reference Reagent. This method could be used for monitoring consistency of IPV production, comparison of vaccines made by different manufacturers, and for the analysis of antigenically modified strains of attenuated poliovirus. Antigenic structures of two isolates of type 1 vaccine-derived poliovirus (VDPV) were compared with the structures of parental Sabin 1 and wild-type Mahoney strains using 17 monoclonal antibodies and revealed significant differences, suggesting that the method can be used for screening of field isolates and rapid identification of antigenically divergent VDPV strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713554     DOI: 10.1016/j.biologicals.2004.11.001

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  7 in total

1.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Fluorescence correlation spectroscopy as a sensitive and useful tool for revealing potential overlaps between the epitopes of monoclonal antibodies on viral particles.

Authors:  Ludovic Richert; Nicolas Humbert; Eric Larquet; Yves Girerd-Chambaz; Catherine Manin; Frédéric Ronzon; Yves Mély
Journal:  MAbs       Date:  2016-07-18       Impact factor: 5.857

3.  Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.

Authors:  Maria L Yakovenko; Elena A Cherkasova; Gennady V Rezapkin; Olga E Ivanova; Alexander P Ivanov; Tatyana P Eremeeva; Olga Y Baykova; Konstantin M Chumakov; Vadim I Agol
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 4.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

5.  Effect of formaldehyde inactivation on poliovirus.

Authors:  Thomas Wilton; Glynis Dunn; David Eastwood; Philip D Minor; Javier Martin
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

6.  Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Authors:  Maren Eggers; Elena Terletskaia-Ladwig; Holger F Rabenau; Hans W Doerr; Sabine Diedrich; Gisela Enders; Martin Enders
Journal:  BMC Infect Dis       Date:  2010-12-09       Impact factor: 3.090

7.  A novel gamma radiation-inactivated sabin-based polio vaccine.

Authors:  Gregory J Tobin; John K Tobin; Elena K Gaidamakova; Taralyn J Wiggins; Ruth V Bushnell; Wai-Ming Lee; Vera Y Matrosova; Stephen J Dollery; Heather N Meeks; Diana Kouiavskaia; Konstantin Chumakov; Michael J Daly
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.